Flonics Co.

FLONICS, founded in 2024 in Chuncheon, South Korea, specializes in developing medical imaging software for blood flow analysis.FLONICS, Inc. specializes in the development of advanced medical imaging-based software solutions designed for automated blood flow analysis. The company’s core offerings include innovative software products that utilize cutting-edge 4D flow MRI technology to facilitate precise hemodynamic assessments for cardiovascular and cerebrovascular conditions. These solutions are particularly aimed at addressing critical health issues such as atherosclerosis, aortic aneurysms, and aortic dissection, providing clinicians with tools to enhance diagnostic accuracy, treatment planning, and patient management. The automated all-in-one solution streamlines the processes of imaging, analysis, and reporting, significantly improving efficiency in clinical workflows.FLONICS generates revenue through the sale and licensing of its proprietary software products, including flagship solutions like MR-Cath and Virtual-Cath, which replace traditional invasive catheter pressure measurements with non-invasive methods. Transactions typically occur on a B2B basis, with healthcare institutions purchasing licenses for the software, potentially structured as annual subscriptions or one-time fees depending on the service agreement. Revenue may also be derived from partnerships and collaborations with medical device manufacturers and educational institutions, enhancing the reach and application of their technology in clinical settings. The company plans to expand its product line with new software solutions aimed at improving diagnostic capabilities, targeting release dates in the coming year.

1. Seed

   Aug 26, 2025

   Amount

   $0.7M

   Investors

   Locked